These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31581859)

  • 1. Off-label studies on tofacitinib in dermatology: a review.
    Tegtmeyer K; Zhao J; Maloney NJ; Atassi G; Beestrum M; Lio PA
    J Dermatolog Treat; 2021 Jun; 32(4):399-409. PubMed ID: 31581859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Dai Q; Zhang Y; Liu Q; Zhang C
    Clin Rheumatol; 2024 May; 43(5):1605-1613. PubMed ID: 38517652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label studies on apremilast in dermatology: a review.
    Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
    J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
    Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
    Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The off-label uses profile of tofacitinib in systemic rheumatic diseases.
    Zhao Z; Ye C; Dong L
    Int Immunopharmacol; 2020 Jun; 83():106480. PubMed ID: 32283509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Ighani A; Georgakopoulos JR; Yeung J
    G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label studies on ruxolitinib in dermatology: a review.
    Wu J; Smogorzewski J
    J Dermatolog Treat; 2022 Mar; 33(2):606-612. PubMed ID: 32515635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
    Asahina A; Etoh T; Igarashi A; Imafuku S; Saeki H; Shibasaki Y; Tomochika Y; Toyoizumi S; Nagaoka M; Ohtsuki M;
    J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib in psoriatic arthritis.
    Wang TS; Tsai TF
    Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A; Mahmood F; Wittmann M; Helliwell P
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
    J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 15. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Gupta AK; Cernea M; Lynde CW
    Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
    Yu DA; Kim YE; Kwon O; Park H
    Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
    Mahadevan U; Dubinsky MC; Su C; Lawendy N; Jones TV; Marren A; Zhang H; Graham D; Clowse MEB; Feldman SR; Baumgart DC
    Inflamm Bowel Dis; 2018 Nov; 24(12):2494-2500. PubMed ID: 29982686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
    Tian F; Chen Z; Xu T
    J Int Med Res; 2019 Jun; 47(6):2342-2350. PubMed ID: 31096817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.